Table 2.
Correlation between the expression of ERCC3 and clinicopathologic parameters in pancreatic cancer
| Characteristics | Total | Expression of ERCC3 | p value | |
|---|---|---|---|---|
| Low | High | |||
| Gender | ||||
| Male | 35 | 2 | 33 | 0.640a |
| Female | 25 | 3 | 22 | |
| Age at surgery | ||||
| <60 | 21 | 2 | 19 | 1.000a |
| ≥60 | 39 | 3 | 36 | |
| Tumor extent | ||||
| T1/2 | 8 | 3 | 5 | 0.035a |
| T3/4 | 36 | 2 | 34 | |
| Lymph node metastasis | ||||
| N0 | 33 | 3 | 30 | 1.000a |
| N1 | 25 | 2 | 23 | |
| Distant metastasis | ||||
| M0 | 56 | 4 | 52 | 0.301a |
| M1 | 4 | 1 | 3 | |
| Tumor max diameter (cm) | ||||
| <4 | 21 | 2 | 19 | 1.000a |
| ≥4 | 39 | 3 | 36 | |
| Histologic grade | ||||
| G1-2 | 35 | 2 | 33 | 0.640a |
| G3 | 25 | 3 | 22 | |
| TNM stage | ||||
| I/II | 47 | 4 | 43 | 0.347a |
| III/IV | 4 | 1 | 3 | |
Data was not available (NA) for some cases: Tumor extent (NA = 16), Lymph node metastasis (NA = 2), TNM stage (NA = 9);
a, Fisher exact test;
Significant p-value is in bold.